Elderly Patients with Chronic Myeloid Leukemia Benefit from a Dasatinib dose as Low as 20 mg

A retrospective study of elderly chronic myeloid leukemia (CML) patients aged ≥ 65 years was conducted to evaluate the efficacy and safety of low-dose dasatinib treatment. Reducing the dose of dasatinib below 100 mg/day (even to ≤ 20 mg/day) generated good responses in these patients. The doses were safe and induced rapid and deep molecular responses.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research